Skip to main content

Table 1 Baseline patient characteristics

From: OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review

Characteristic

Upper-limb spasticity

Lower-limb spasticity

 

k

t

n/N

Frequency (%)

k

t

n/N

Frequency (%)

Total

44

59*

1,670

--

37

47

1,347

--

Gender

36

47

1,464

100.0

31

40

1,200

100.0

Male

36

47

883/1,464

60.3

31

40

699/1,200

58.3

Female

36

47

581/1,464

39.7

31

39

501/1,200

41.8

Spasticity origin

44

59

1,670

100.0

37

47

1,347

100.0

Stroke only

24

31

1,105/1,670

66.2

16

21

837/1,347

62.1

Stroke/Traumatic brain injury

6

8

107/1,670

6.4

3

3

70/1,347

5.2

Traumatic brain injury only

1

2

21/1,670

1.3

1

1

7/1,347

0.5

Multiple sclerosis

2

3

43/1,670

2.6

5

6

80/1,347

5.9

Spinal cord injury

1

1

28/1,670

1.7

1

2

36/1,347

2.7

Mixed/Other

10

14

366/1,670

21.9

11

14

317/1,347

23.5

 

k

t

Mean

Range of means

k

t

Mean

Range of means

Age (years)

39

53

51.7

26 – 66.3

35

45

49.9

26 – 66.3

Time since onset (months)

31

43

46.9

4.7 – 120

26

34

53.6

0.35 – 218.4

  1. k = Number of studies, t = Number of treatment arms, n = Number of patients with this characteristic, N = Total number of patients in treatment arms reporting characteristic. *The 44 studies that reported on patients with upper-limb spasticity had a total of 59 onabotulinumtoxinA treatment arms; however, only 58 of these arms consisted of at least 1 patient with upper-limb spasticity, as shown in Table 2.